Orthopedics In Brief
This article was originally published in The Gray Sheet
Executive Summary
New CEO for Wright: Gary Henley will take the helm from interim CEO Barry Bays at Wright Medical, effective April 4. Henley brings 24 years of experience in the orthopedic industry. He has been with Orthofix since 1997, spending the past four years as president of the Americas division, and also draws on nearly ten years of experience with Smith & Nephew. Bays has held the interim CEO position since Laurence Fairey resigned the post in October following disappointing third-quarter results (1"The Gray Sheet" Dec. 12, 2005, p. 13). Bays will resume his role as executive chairman, the firm says...
You may also be interested in...
Orthopedics In Brief
Medtronic set to begin spinal stabilization trial: Firm is enrolling patients for the first of three clinical trials evaluating the use of its Diam spinal stabilization system. Medtronic announced IDE clearance to begin studies of the nonfusion spinal stabilization system on July 10. Diam relieves spine pressure by rerouting spinal load, similar to St. Francis Medical's X-Stop device, PMA approved in 2005. Medtronic's initial study, slated to begin in August, will examine the safety and effectiveness of the Diam system in patients with degenerative stenosis. The second trial, to begin in Europe in September, will compare discectomy with Diam to discectomy alone. A third study will evaluate Diam's use in degenerative disc disease. Medtronic expects to enroll a total of 430 patients in up to 25 centers in the U.S. and Europe...
Orthopedics In Brief
Medtronic set to begin spinal stabilization trial: Firm is enrolling patients for the first of three clinical trials evaluating the use of its Diam spinal stabilization system. Medtronic announced IDE clearance to begin studies of the nonfusion spinal stabilization system on July 10. Diam relieves spine pressure by rerouting spinal load, similar to St. Francis Medical's X-Stop device, PMA approved in 2005. Medtronic's initial study, slated to begin in August, will examine the safety and effectiveness of the Diam system in patients with degenerative stenosis. The second trial, to begin in Europe in September, will compare discectomy with Diam to discectomy alone. A third study will evaluate Diam's use in degenerative disc disease. Medtronic expects to enroll a total of 430 patients in up to 25 centers in the U.S. and Europe...
Biomet CEO quits
After nearly 20 years at the orthopedics firm, CEO and co-founder Dane Miller, PhD, resigned on March 27. Effectively immediately, Senior VP Daniel Hann, who joined the company in 1989, will command the top spot following Miller's departure. Miller will remain director of the board and will serve as a consultant to the company. "I'm not out of the game, just sitting on the bench right beside our new coach," Miller said during a March 27 call. Miller has served as CEO of the firm since its formation in 1977 and the decision was unexpected by many in the industry, especially after Miller headlined the Biomet's AAOS presentation just the week prior. However, it appears that several months of declines in both stock price and revenue growth likely forced his decision (1"The Gray Sheet" March 27, 2006, p.13)...